JP2003524368A - ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、dna結合ドメインまたはリガンド結合ドメインを含む融合蛋白 - Google Patents

ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、dna結合ドメインまたはリガンド結合ドメインを含む融合蛋白

Info

Publication number
JP2003524368A
JP2003524368A JP2000507818A JP2000507818A JP2003524368A JP 2003524368 A JP2003524368 A JP 2003524368A JP 2000507818 A JP2000507818 A JP 2000507818A JP 2000507818 A JP2000507818 A JP 2000507818A JP 2003524368 A JP2003524368 A JP 2003524368A
Authority
JP
Japan
Prior art keywords
domain
nucleic acid
fusion protein
bundling
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000507818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003524368A5 (enExample
Inventor
ネイトサン,スリダラン
ズィー ギルマン,マイケル
Original Assignee
アリアド ジーン セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/920,610 external-priority patent/US6015709A/en
Priority claimed from PCT/US1997/015219 external-priority patent/WO1999010508A1/en
Application filed by アリアド ジーン セラピューティクス インコーポレイテッド filed Critical アリアド ジーン セラピューティクス インコーポレイテッド
Publication of JP2003524368A publication Critical patent/JP2003524368A/ja
Publication of JP2003524368A5 publication Critical patent/JP2003524368A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4705Regulators; Modulating activity stimulating, promoting or activating activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1055Protein x Protein interaction, e.g. two hybrid selection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2000507818A 1997-08-26 1998-08-26 ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、dna結合ドメインまたはリガンド結合ドメインを含む融合蛋白 Pending JP2003524368A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US91840197A 1997-08-26 1997-08-26
US08/918,401 1997-08-26
US08/920,610 US6015709A (en) 1997-08-26 1997-08-27 Transcriptional activators, and compositions and uses related thereto
PCT/US1997/015219 WO1999010508A1 (en) 1997-08-27 1997-08-27 Chimeric transcriptional activators and compositions and uses related thereto
US08/920,610 1997-08-27
US9715219 1997-08-27
US12600998A 1998-07-29 1998-07-29
US09/126,009 1998-07-29
PCT/US1998/017723 WO1999010510A2 (en) 1997-08-26 1998-08-26 Fusion proteins comprising a dimerization, trimerization or tetramerization domain and an additional heterologous transcription activation, transcription repression, dna binding or ligand binding domain

Publications (2)

Publication Number Publication Date
JP2003524368A true JP2003524368A (ja) 2003-08-19
JP2003524368A5 JP2003524368A5 (enExample) 2006-01-05

Family

ID=27492886

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000507818A Pending JP2003524368A (ja) 1997-08-26 1998-08-26 ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、dna結合ドメインまたはリガンド結合ドメインを含む融合蛋白

Country Status (6)

Country Link
US (1) US6117680A (enExample)
EP (1) EP1017829A2 (enExample)
JP (1) JP2003524368A (enExample)
AU (1) AU9036198A (enExample)
CA (1) CA2300376A1 (enExample)
WO (1) WO1999010510A2 (enExample)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6891021B2 (en) * 1993-02-12 2005-05-10 Board Of Trustees Of The Leland Stanford Junior University Regulated apoptosis
US6972193B1 (en) * 1993-02-12 2005-12-06 Board Of Trustees Of Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
CA2372199A1 (en) * 1999-05-14 2000-11-23 Medical Research Council Oligomeric chaperone proteins
WO2000069907A1 (en) * 1999-05-14 2000-11-23 Medical Research Council Protein scaffold and its use to multimerise monomeric polypeptides
WO2000071743A1 (fr) * 1999-05-25 2000-11-30 Eisai Co., Ltd. Methode bihybride dans une cellule de mammifere
EP1181360A1 (en) * 1999-05-28 2002-02-27 Sangamo Biosciences Inc. Molecular switches
AU783037B2 (en) * 1999-05-28 2005-09-15 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (TNF) in the TNF-associated disorders
US7057015B1 (en) 1999-10-20 2006-06-06 The Salk Institute For Biological Studies Hormone receptor functional dimers and methods of their use
WO2001036623A2 (en) * 1999-11-05 2001-05-25 Avigen, Inc. Ecdysone-inducible adeno-associated virus expression vectors
AU2001229741A1 (en) 2000-01-24 2001-07-31 The Trustees Of Columbia University In The City Of New York An in vivo screen using chemical inducers of dimerization
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
EP1266015B1 (en) * 2000-03-22 2006-08-30 RheoGene Holdings Inc. Ecdysone receptor-based inducible gene expression system
EP1290196A1 (en) * 2000-06-16 2003-03-12 Ariad Gene Therapeutics, Inc. Chimeric hsf transcription factors
JP2004504029A (ja) * 2000-07-18 2004-02-12 ノバルティス アクチエンゲゼルシャフト 単鎖、一量体、リガンド依存性ポリペプチドスイッチを用いる遺伝子発現の調節
US7011972B2 (en) 2000-07-18 2006-03-14 The Scripps Research Institute Fusion polypeptide comprising two ligand binding domains
CA2416664A1 (en) * 2000-07-21 2002-01-31 Syngenta Participations Ag Zinc finger domain recognition code and uses thereof
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
US6576422B1 (en) 2000-10-17 2003-06-10 Rohm And Haas Company Method for identifying products employing gene expression
JP4955905B2 (ja) 2001-02-20 2012-06-20 イントレキソン コーポレーション キメラレチノイドx受容体および新規エクジソン受容体−ベースの誘導性遺伝子発現システムにおけるそれらの使用
JP4994563B2 (ja) 2001-02-20 2012-08-08 イントレキソン コーポレーション 新規置換突然変異体受容体および核受容体−ベースの誘導性遺伝子発現システムにおけるその使用
WO2002066613A2 (en) 2001-02-20 2002-08-29 Rheogene Holdings, Inc Novel ecdysone receptor/invertebrate retinoid x receptor-based inducible gene expression system
DK1373470T3 (da) 2001-02-20 2013-07-29 Intrexon Corp Hidtil ukendte substitutionsmutantreceptorer og deres anvendelse i et cellekernereceptorbaseret inducerbart genekspressionssystem
WO2002070662A2 (en) * 2001-03-02 2002-09-12 Gpc Biotech Ag Three hybrid assay system
WO2003016496A2 (en) * 2001-08-20 2003-02-27 The Scripps Research Institute Zinc finger binding domains for cnn
WO2003018777A1 (en) * 2001-08-23 2003-03-06 The Regents Of The University Of California A universal light-switchable gene promoter system
AU2002339863A1 (en) * 2001-08-31 2003-03-18 Abmaxis, Inc. Multivalent protein conjugate with multiple ligand-binding domains of receptors
US7563879B2 (en) 2001-09-26 2009-07-21 Intrexon Corporation Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof
CA2462598A1 (en) * 2001-10-01 2003-04-10 Bioimage A/S A method of detecting intracellular protein-protein interactions using three heterologous conjugates
US20060270043A1 (en) * 2002-01-23 2006-11-30 Blattner Frederick R Bacteria with reduced genome
US8765408B2 (en) 2002-01-23 2014-07-01 Wisconsin Alumni Research Foundation Prophage element-free bacteria
US8039243B2 (en) * 2002-01-23 2011-10-18 Wisconsin Alumni Research Foundation Insertion sequence-free bacteria
US8119365B2 (en) * 2002-01-23 2012-02-21 Wisconsin Alumni Research Foundation Insertion sequence-free bacteria
US6989265B2 (en) * 2002-01-23 2006-01-24 Wisconsin Alumni Research Foundation Bacteria with reduced genome
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
US6845929B2 (en) * 2002-03-22 2005-01-25 Ali Dolatabadi High efficiency nozzle for thermal spray of high quality, low oxide content coatings
US7083918B2 (en) 2002-04-24 2006-08-01 The Trustees Of Columbia University In The City Of New York Bacterial small-molecule three-hybrid system
DK1531666T3 (da) * 2002-05-29 2014-01-13 Regeneron Pharma Inducerbart eukaryot-ekspressionssystem
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US7303906B2 (en) * 2002-09-06 2007-12-04 Wisconsin Alumni Research Foundation Competent bacteria
CA2503787A1 (en) * 2002-11-05 2004-05-27 Regeneron Pharmaceuticals, Inc. Methods of isolation of active compounds and activated targets
US7385027B2 (en) * 2003-01-07 2008-06-10 University Of Kentucky Research Foundation Membrane-permeable peptide capable of calpain inhibition
US7304161B2 (en) 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7456315B2 (en) 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
JP4644663B2 (ja) 2003-06-03 2011-03-02 セル ジェネシス インコーポレイテッド ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
CA2573656A1 (en) * 2004-07-13 2006-02-16 Cell Genesys, Inc. Aav vector compositions and methods for enhanced expression of immunoglobulins using the same
US7632509B2 (en) 2005-07-19 2009-12-15 Biosante Pharmaceuticals, Inc. Methods to express recombinant proteins from lentiviral vectors
US20070292922A1 (en) * 2006-03-31 2007-12-20 Cell Genesys, Inc. Regulated expression of recombinant proteins from adeno-associated viral vectors
MX2010003371A (es) 2007-09-28 2010-05-05 Intrexon Corp Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos.
RU2612788C2 (ru) 2010-03-23 2017-03-13 Интрексон Корпорейшн Векторы, условно экспрессирующие терапевтические белки, клетки-хозяева, содержащие указанные векторы, и их применение
MX342858B (es) 2010-03-29 2016-10-13 The Trustees Of The Univ Of Pennsylvania * Sistema de ablacion transgenica inducida farmacologicamente.
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
AU2012225749B2 (en) 2011-03-04 2015-01-22 Intrexon Corporation Vectors conditionally expressing protein
EP3699286A1 (en) 2011-04-20 2020-08-26 The Trustees of the University of Pennsylvania Regimens and compositions for aav-mediated passive immunization of airborne pathogens
WO2014100913A1 (en) * 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
SG11201506875YA (en) 2013-03-15 2015-09-29 Intrexon Corp Boron-containing diacylhydrazines
WO2015012924A2 (en) 2013-04-29 2015-01-29 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
US10655123B2 (en) * 2014-03-05 2020-05-19 National University Corporation Kobe University Genomic sequence modification method for specifically converting nucleic acid bases of targeted DNA sequence, and molecular complex for use in same
WO2016044390A1 (en) 2014-09-17 2016-03-24 Intrexon Corporation Boron-containing diacylhydrazine compounds
EP3739047A1 (en) * 2014-11-04 2020-11-18 National University Corporation Kobe University Method for modifying genome sequence to introduce specific mutation to targeted dna sequence by base-removal reaction, and molecular complex used therein
US11535665B2 (en) 2015-05-13 2022-12-27 The Trustees Of The University Of Pennsylvania AAV-mediated expression of anti-influenza antibodies and methods of use thereof
EP3347373A1 (en) 2015-10-10 2018-07-18 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
WO2017075335A1 (en) 2015-10-28 2017-05-04 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
CN108495932B (zh) 2015-11-27 2022-08-09 国立大学法人神户大学 用于特异性转换靶向dna序列的核酸碱基的单子叶植物的基因组序列的转换方法、及其使用的分子复合体
AU2017248731B2 (en) 2016-04-15 2024-08-29 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
UY37343A (es) 2016-07-25 2018-02-28 Intrexon Corp Control del fenotipo en plantas
BR112019009446A2 (pt) 2016-11-09 2019-07-30 Intrexon Corp construtos de expressão da frataxina
JP2020510430A (ja) 2017-02-28 2020-04-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Aavベクターに基づくインフルエンザワクチン
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
FI3589730T3 (fi) 2017-02-28 2024-02-22 Univ Pennsylvania Kladin f adenoassosioitunut virus (aav) -vektori ja sen käyttötapoja
CA3079565A1 (en) 2017-10-18 2019-04-25 Regenxbio Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
EP4509527A3 (en) 2017-10-18 2025-04-30 REGENXBIO Inc. Post-translationally modified fully human antibody therapeutic agents
EP3946467A1 (en) 2019-04-03 2022-02-09 REGENXBIO Inc. Gene therapy for eye pathologies
CA3137284A1 (en) 2019-04-24 2020-10-29 Regenxbio Inc. Fully-human post-translationally modified antibody therapeutics
CN114502197A (zh) 2019-08-26 2022-05-13 再生生物股份有限公司 用全人经翻译后修饰的抗VEGF Fab治疗糖尿病性视网膜病变
EP4041292A1 (en) 2019-10-07 2022-08-17 RegenxBio Inc. Adeno-associated virus vector pharmaceutical composition and methods
US20250326861A1 (en) 2020-09-15 2025-10-23 Regenxbio Inc. Vectorized lanadelumab and administration thereof
WO2022060916A1 (en) 2020-09-15 2022-03-24 Regenxbio Inc. Vectorized antibodies for anti-viral therapy
CA3197342A1 (en) 2020-10-07 2022-04-14 Regenxbio Inc. Gene therapy for ocular manifestations of cln2 disease
CA3195967A1 (en) 2020-10-28 2022-05-05 Xu Wang Vectorized anti-tnf-? antibodies for ocular indications
WO2022094157A1 (en) 2020-10-28 2022-05-05 Regenxbio Inc. Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
EP4236974A2 (en) 2020-10-29 2023-09-06 RegenxBio Inc. Vectorized factor xii antibodies and administration thereof
IL302282A (en) 2020-10-29 2023-06-01 Regenxbio Inc Vectorized tnf-alpha antagonists for ocular indications
EP4256065A2 (en) 2020-12-01 2023-10-11 The Trustees of The University of Pennsylvania Novel compositions with tissue-specific targeting motifs and compositions containing same
CA3216004A1 (en) 2021-04-23 2022-10-27 The Trustees Of The University Of Pennsylvania Novel compositions with brain-specific targeting motifs and compositions containing same
US20240384298A1 (en) 2021-10-02 2024-11-21 The Trustees Of The University Of Pennsylvania Novel aav capsids and compositions containing same
KR20240137067A (ko) 2022-01-25 2024-09-19 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 개선된 심장 형질도입 및 간의 탈표적화를 위한 aav 캡시드
EP4507741A1 (en) 2022-04-14 2025-02-19 RegenxBio Inc. Gene therapy for treating an ocular disease
WO2023205610A2 (en) 2022-04-18 2023-10-26 Regenxbio Inc. Hybrid aav capsids
US20250288697A1 (en) 2022-05-03 2025-09-18 Regenxbio Inc. Vectorized anti-tnf-alpha inhibitors for ocular indications
TW202400803A (zh) 2022-05-03 2024-01-01 美商銳進科斯生物股份有限公司 載體化抗補體抗體與補體劑及其投與
IL319873A (en) 2022-09-30 2025-05-01 Regenxbio Inc Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB
WO2024130070A2 (en) 2022-12-17 2024-06-20 The Trustees Of The University Of Pennsylvania Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
KR20250135916A (ko) 2022-12-17 2025-09-15 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 심장 및 골격근 특이적 표적화 모티프를 갖는 재조합 aav 돌연변이체 벡터 및 이를 포함하는 조성물
WO2024238867A1 (en) 2023-05-16 2024-11-21 Regenxbio Inc. Vectorized anti-complement antibodies and administration thereof
WO2024238859A1 (en) 2023-05-16 2024-11-21 Regenxbio Inc. Vectorized c5 inhibitor agents and administration thereof
TW202516019A (zh) 2023-06-29 2025-04-16 賓州大學委員會 具中樞神經系統靶向模體的突變aav及含有其之組成物
WO2025102034A1 (en) 2023-11-10 2025-05-15 The Trustees Of The University Of Pennsylvania Gene therapy for barth syndrome
WO2025106661A1 (en) 2023-11-14 2025-05-22 The Trustees Of The University Of Pennsylvania Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof
WO2025217230A1 (en) 2024-04-08 2025-10-16 Regenxbio Inc. Vectorized anti-complement antibodies and complement agents and administration thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215909A (en) * 1986-06-18 1993-06-01 Yeda Research & Development Co., Ltd. Human cholinesterase genes
DE69132411T2 (de) * 1990-02-09 2001-06-07 The Salk Institute For Biological Studies, La Jolla Retinoid-rezeptor-zusammensetzungen und verfahren
DE69332981T2 (de) * 1992-10-23 2004-05-19 Immunex Corp., Seattle Methoden zur herstellung löslicher, oligomerer proteine
US5573925A (en) * 1994-11-28 1996-11-12 The Wistar Institute Of Anatomy And Biology P53 proteins with altered tetramerization domains
CA2233031A1 (en) * 1995-09-26 1997-04-03 Beth Israel Deaconess Medical Center, Inc. Gene therapy with modified p65 proteins
US5925523A (en) * 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof

Also Published As

Publication number Publication date
AU9036198A (en) 1999-03-16
EP1017829A2 (en) 2000-07-12
WO1999010510A3 (en) 1999-07-08
CA2300376A1 (en) 1999-03-04
WO1999010510A2 (en) 1999-03-04
US6117680A (en) 2000-09-12

Similar Documents

Publication Publication Date Title
US6117680A (en) Compositions and methods for regulation of transcription
US6479653B1 (en) Compositions and method for regulation of transcription
AU752129B2 (en) Chimeric transcriptional activators and compositions and uses related thereto
US20010049144A1 (en) Methods for high level expression of genes in primates
US7109317B1 (en) FK506-based regulation of biological events
JP2002508971A (ja) 多量体キメラ蛋白質を使用する生物学的イベントの調節
JP2024043538A (ja) B型肝炎ワクチンおよびその使用
US6566073B1 (en) Materials and methods involving conditional retention domains
JP2004500884A (ja) 遺伝子発現の調節方法及び手段
JP2002529081A (ja) 生物学的事象のfk506に基づく調節
JP2002535959A (ja) 条件保持ドメインを含む材料および方法
JP2002507384A (ja) アデノウイルスベクターの製造方法、それによって製造したベクターおよびその使用
AU5618200A (en) Chimeric oca-b transcription factors
EP1290196A1 (en) Chimeric hsf transcription factors
JP2002535958A (ja) 条件集合ドメインに関する材料および方法
US20040265288A1 (en) New applications of gene therapy technology

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080722

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081216